Antibodies to modified citrullinated vimentin are associated with severe extra-articular manifestations in rheumatoid arthritis

Annals of the Rheumatic Diseases

Volumn 72, Issue 12, 2013, Pages 2047-2048

  Turesson, Carl ^a   Mathsson, Linda ^b   Jacobsson, Lennart T H ^a,c   Sturfelt, Gunnar ^a   Rönnelid, Johan ^b  

^a LUND UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; MODIFIED CITRULLINATED VIMENTIN ANTIBODY; RHEUMATOID FACTOR; UNCLASSIFIED DRUG;

AGED; ANTIBODY BLOOD LEVEL; ARTHROPATHY; BLOOD ANALYSIS; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE SEVERITY; ELISA KIT; FELTY SYNDROME; FEMALE; HUMAN; JOINT SWELLING; LETTER; MALE; NEUROPATHY; PERICARDITIS; PLEURISY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; RHEUMATOID ARTHRITIS; VASCULITIS;

ANT-CCP; RHEUMATOID ARTHRITIS; SYSTEMIC VASCULITIS;

AGED; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; CASE-CONTROL STUDIES; CITRULLINE; FEMALE; HUMANS; MALE; MIDDLE AGED; VIMENTIN;

EID: 84887465407     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-203510     Document Type: Letter

References (9)

1. Schellekens GA, Visser H, De Jong BA, et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 2000;43:155-63.
2. Kroot EJ, De Jong BA, Van Leeuwen MA, et al. The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 2000;43:1831-5.
3. Turesson C, Jacobsson LT, Sturfelt G, et al. Rheumatoid factor and antibodies to cyclic citrullinated peptides are associated with severe extra-articular manifestations in rheumatoid arthritis. Ann Rheum Dis 2007;66:59-64.
4. Boire G, Cossette P, De Brum-Fernandes AJ, et al. Anti-Sa antibodies and antibodies against cyclic citrullinated peptide are not equivalent as predictors of severe outcomes in patients with recent-onset polyarthritis. Arthritis Res Ther 2005;7:R592-603.
5. Vossenaar ER, Despres N, Lapointe E, et al. Rheumatoid arthritis specific anti-Sa antibodies target citrullinated vimentin. Arthritis Res Ther 2004;6:R142-50.
6. Bartoloni E, Alunno A, Bistoni O, et al. Diagnostic value of anti-mutated citrullinated vimentin in comparison to anti-cyclic citrullinated peptide and anti-viral citrullinated peptide 2 antibodies in rheumatoid arthritis: an Italian multicentric study and review of the literature. Autoimmun Rev 2012;11:815-20.
7. Turesson C, O'Fallon WM, Crowson CS, et al. Occurrence of extraarticular disease manifestations is associated with excess mortality in a community based cohort of patients with rheumatoid arthritis. J Rheumatol 2002;29:62-7.
8. Bang H, Egerer K, Gauliard A, et al. Mutation and citrullination modifies vimentin to a novel autoantigen for rheumatoid arthritis. Arthritis Rheum 2007;56:2503-11.
9. Mathsson L, Mullazehi M, Wick MC, et al. Antibodies against citrullinated vimentin in rheumatoid arthritis: higher sensitivity and extended prognostic value concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptides. Arthritis Rheum 2008;58:36-45.